81 related articles for article (PubMed ID: 21441227)
1. A twenty-eight-day mechanistic time course study in the rhesus monkey with hepatitis C virus protease inhibitor BILN 2061.
Stoltz JH; Stern JO; Huang Q; Seidler RW; Pack FD; Knight BL
Toxicol Pathol; 2011 Apr; 39(3):496-501. PubMed ID: 21441227
[TBL] [Abstract][Full Text] [Related]
2. Ultra-rapid cardiotoxicity of the hepatitis C virus protease inhibitor BILN 2061 in the urokinase-type plasminogen activator mouse.
Vanwolleghem T; Meuleman P; Libbrecht L; Roskams T; De Vos R; Leroux-Roels G
Gastroenterology; 2007 Oct; 133(4):1144-55. PubMed ID: 17919490
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of BILN 2061, an HCV NS3 protease inhibitor with proven antiviral effect in humans.
Faucher AM; Bailey MD; Beaulieu PL; Brochu C; Duceppe JS; Ferland JM; Ghiro E; Gorys V; Halmos T; Kawai SH; Poirier M; Simoneau B; Tsantrizos YS; Llinàs-Brunet M
Org Lett; 2004 Aug; 6(17):2901-4. PubMed ID: 15330643
[TBL] [Abstract][Full Text] [Related]
4. The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061--from the NMR tube to the clinic.
Tsantrizos YS
Biopolymers; 2004; 76(4):309-23. PubMed ID: 15386268
[TBL] [Abstract][Full Text] [Related]
5. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C.
Reiser M; Hinrichsen H; Benhamou Y; Reesink HW; Wedemeyer H; Avendano C; Riba N; Yong CL; Nehmiz G; Steinmann GG
Hepatology; 2005 Apr; 41(4):832-5. PubMed ID: 15732092
[TBL] [Abstract][Full Text] [Related]
6. Resistance of hepatitis C virus to NS3-4A protease inhibitors: mechanisms of drug resistance induced by R155Q, A156T, D168A and D168V mutations.
Courcambeck J; Bouzidi M; Perbost R; Jouirou B; Amrani N; Cacoub P; Pèpe G; Sabatier JM; Halfon P
Antivir Ther; 2006; 11(7):847-55. PubMed ID: 17302247
[TBL] [Abstract][Full Text] [Related]
7. Mechanistic and kinetic characterization of hepatitis C virus NS3 protein interactions with NS4A and protease inhibitors.
Geitmann M; Dahl G; Danielson UH
J Mol Recognit; 2011; 24(1):60-70. PubMed ID: 21194118
[TBL] [Abstract][Full Text] [Related]
8. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus.
Lamarre D; Anderson PC; Bailey M; Beaulieu P; Bolger G; Bonneau P; Bös M; Cameron DR; Cartier M; Cordingley MG; Faucher AM; Goudreau N; Kawai SH; Kukolj G; Lagacé L; LaPlante SR; Narjes H; Poupart MA; Rancourt J; Sentjens RE; St George R; Simoneau B; Steinmann G; Thibeault D; Tsantrizos YS; Weldon SM; Yong CL; Llinàs-Brunet M
Nature; 2003 Nov; 426(6963):186-9. PubMed ID: 14578911
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061.
Thibeault D; Bousquet C; Gingras R; Lagacé L; Maurice R; White PW; Lamarre D
J Virol; 2004 Jul; 78(14):7352-9. PubMed ID: 15220408
[TBL] [Abstract][Full Text] [Related]
10. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
López-Labrador FX; Moya A; Gonzàlez-Candelas F
Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527
[TBL] [Abstract][Full Text] [Related]
11. Bismacrocyclic inhibitors of hepatitis C NS3/4a protease.
McCauley JA; Rudd MT; Nguyen KT; McIntyre CJ; Romano JJ; Bush KJ; Varga SL; Ross CW; Carroll SS; DiMuzio J; Stahlhut MW; Olsen DB; Lyle TA; Vacca JP; Liverton NJ
Angew Chem Int Ed Engl; 2008; 47(47):9104-7. PubMed ID: 18925594
[No Abstract] [Full Text] [Related]
12. Protease and helicase activities of hepatitis C virus genotype 4, 5, and 6 NS3-NS4A proteins.
Massariol MJ; Zhao S; Marquis M; Thibeault D; White PW
Biochem Biophys Res Commun; 2010 Jan; 391(1):692-7. PubMed ID: 19944069
[TBL] [Abstract][Full Text] [Related]
13. Efficient large-scale synthesis of BILN 2061, a potent HCV protease inhibitor, by a convergent approach based on ring-closing metathesis.
Yee NK; Farina V; Houpis IN; Haddad N; Frutos RP; Gallou F; Wang XJ; Wei X; Simpson RD; Feng X; Fuchs V; Xu Y; Tan J; Zhang L; Xu J; Smith-Keenan LL; Vitous J; Ridges MD; Spinelli EM; Johnson M; Donsbach K; Nicola T; Brenner M; Winter E; Kreye P; Samstag W
J Org Chem; 2006 Sep; 71(19):7133-45. PubMed ID: 16958506
[TBL] [Abstract][Full Text] [Related]
14. Discovery of novel potent and selective dipeptide hepatitis C virus NS3/4A serine protease inhibitors.
Raboisson P; Lin TI; Kock Hd; Vendeville S; Vreken WV; McGowan D; Tahri A; Hu L; Lenz O; Delouvroy F; Surleraux D; Wigerinck P; Nilsson M; Rosenquist S; Samuelsson B; Simmen K
Bioorg Med Chem Lett; 2008 Sep; 18(18):5095-100. PubMed ID: 18722116
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061.
Llinàs-Brunet M; Bailey MD; Bolger G; Brochu C; Faucher AM; Ferland JM; Garneau M; Ghiro E; Gorys V; Grand-Maître C; Halmos T; Lapeyre-Paquette N; Liard F; Poirier M; Rhéaume M; Tsantrizos YS; Lamarre D
J Med Chem; 2004 Mar; 47(7):1605-8. PubMed ID: 15027850
[TBL] [Abstract][Full Text] [Related]
16. Novel robust hepatitis C virus mouse efficacy model.
Zhu Q; Oei Y; Mendel DB; Garrett EN; Patawaran MB; Hollenbach PW; Aukerman SL; Weiner AJ
Antimicrob Agents Chemother; 2006 Oct; 50(10):3260-8. PubMed ID: 17005803
[TBL] [Abstract][Full Text] [Related]
17. Antiviral interactions of an HCV polymerase inhibitor with an HCV protease inhibitor or interferon in vitro.
Koev G; Dekhtyar T; Han L; Yan P; Ng TI; Lin CT; Mo H; Molla A
Antiviral Res; 2007 Jan; 73(1):78-83. PubMed ID: 16945431
[TBL] [Abstract][Full Text] [Related]
18. Estimation of inhibitory quotient using a comparative equilibrium dialysis assay for prediction of viral response to hepatitis C virus inhibitors.
Mo H; Yang C; Wang K; Wang Y; Huang M; Murray B; Qi X; Sun SC; Deshpande M; Rhodes G; Miller MD
J Viral Hepat; 2011 May; 18(5):338-48. PubMed ID: 20456634
[TBL] [Abstract][Full Text] [Related]
19. In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061.
Lin C; Gates CA; Rao BG; Brennan DL; Fulghum JR; Luong YP; Frantz JD; Lin K; Ma S; Wei YY; Perni RB; Kwong AD
J Biol Chem; 2005 Nov; 280(44):36784-91. PubMed ID: 16087668
[TBL] [Abstract][Full Text] [Related]
20. Probing the cation binding modes of macrocyclic HCV protease inhibitor BILN 2061 by multinuclear NMR.
Busacca CA; Jones PJ; Campbell SJ; Saha AK; Gonnella NC; Senanayake CH
J Pharm Biomed Anal; 2012 Nov; 70():609-13. PubMed ID: 22766359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
